Success Metrics

Clinical Success Rate
71.4%

Based on 15 completed trials

Completion Rate
71%(15/21)
Active Trials
1(4%)
Results Posted
60%(9 trials)
Terminated
6(23%)

Phase Distribution

Ph phase_3
3
12%
Ph phase_4
4
15%
Ph not_applicable
2
8%
Ph phase_1
9
35%
Ph phase_2
8
31%

Phase Distribution

9

Early Stage

8

Mid Stage

7

Late Stage

Phase Distribution26 total trials
Phase 1Safety & dosage
9(34.6%)
Phase 2Efficacy & side effects
8(30.8%)
Phase 3Large-scale testing
3(11.5%)
Phase 4Post-market surveillance
4(15.4%)
N/ANon-phased studies
2(7.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

68.2%

15 of 22 finished

Non-Completion Rate

31.8%

7 ended early

Currently Active

1

trials recruiting

Total Trials

26

all time

Status Distribution
Active(1)
Completed(15)
Terminated(7)
Other(3)

Detailed Status

Completed15
Terminated6
unknown3
Withdrawn1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
26
Active
1
Success Rate
71.4%
Most Advanced
Phase 4

Trials by Phase

Phase 19 (34.6%)
Phase 28 (30.8%)
Phase 33 (11.5%)
Phase 44 (15.4%)
N/A2 (7.7%)

Trials by Status

withdrawn14%
completed1558%
unknown312%
active_not_recruiting14%
terminated623%

Recent Activity

1 active trials
Showing 5 of 26
active_not_recruitingphase_3

High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

NCT00003641
completedphase_3

Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma

NCT01359956
terminatedphase_4

Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas

NCT02323659
completedphase_1

A Phase I Trial of Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor (rHuGM-CSF), Recombinant Alpha Interferon and Azidothymidine (AZT) in AIDS-Associated Kaposi's Sarcoma

NCT00000694
completedphase_2

The Safety and Effectiveness of Interferon Alfa-2B Plus Didanosine in Patients With Kaposi's Sarcoma

NCT00001114
View all 26 trials

Clinical Trials (26)

Showing 20 of 26 trialsScroll for more
NCT00003641Phase 3

High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

Active Not Recruiting
NCT01359956Phase 3

Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma

Completed
NCT02323659Phase 4

Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas

Terminated
NCT00000694Phase 1

A Phase I Trial of Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor (rHuGM-CSF), Recombinant Alpha Interferon and Azidothymidine (AZT) in AIDS-Associated Kaposi's Sarcoma

Completed
NCT00001114Phase 2

The Safety and Effectiveness of Interferon Alfa-2B Plus Didanosine in Patients With Kaposi's Sarcoma

Completed
NCT02151448Phase 1

αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies

Completed
NCT02174172Phase 1

A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors

Completed
NCT00919633Phase 2

Safety and Efficacy Study to Compare Continuous Infusion of Interferon With Standard of Care for Chronic Hepatitis C

Completed
NCT03547154Phase 2

Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^® A) in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026)

Terminated
NCT03537274Phase 2

Efficacy of Polyethylene Glycol-Interferon Alfa-2B (PEG-Intron, SCH 54031) Compared to Interferon Alfa-2B in Participants With Chronic Hepatitis C (MK-4031-016)

Completed
NCT02185261Not Applicable

Interferon α for the Therapy of Minimal Residual Disease

Unknown
NCT02360592Phase 4

Combination Therapy With Interferon Plus Interleukin 2 and Hepatitis B Vaccine in Chronic Hepatitis B Patients

Completed
NCT00854581Phase 4

Zidovudine, Interferon Alfa-2b, PEG-Interferon Alfa-2b in Patients With HTLV-I Associated Adult T-Cell Leukemia/Lymphoma

Terminated
NCT02199327Phase 4

Topical Interferon Alfa 2b and Mitomycin C in Conjunctival-Corneal Intraepithelial Neoplasia

Completed
NCT01409174Phase 1

IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma

Terminated
NCT01217359Phase 1

Differences in Evoked Intracellular Interferon Signaling Pathways Using Single Cell Phosphoprotein Profiling

Completed
NCT02568241Phase 1

Interferon-α After DLI for the Prevention of Relapse

Unknown
NCT01462773Phase 1

Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma

Completed
NCT01274273Phase 2

Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer

Unknown
NCT01639885Phase 1

Chemo-immunotherapy (Gemcitabine, Interferon-alpha 2b and p53 SLP) in Patients With Platinum-resistant Ovarian Cancer

Completed

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
26